R&D channel feed

J&J beats No­var­tis' block­buster ri­val in a head-to-head show­down over the pso­ri­a­sis mar­ket

7 years ago

Too much suc­cess? A boom­ing biotech pipeline will spur in­tense ri­val­ries — an­a­lyst

7 years ago
Pharma

As­traZeneca, Can­cer Re­search UK set up ge­nomics hub to fight up­hill bat­tle against can­cer

7 years ago
Discovery

0-for-2: An­oth­er fad­ed drug star in Ax­o­van­t's much-hyped pipeline falls, tar­nish­ing Ra­maswamy's deal-mak­ing rep

7 years ago

FDA slaps par­tial hold on Macro­Gen­ics for bis­pe­cif­ic can­cer tri­als as liv­er tox spurs safe­ty fears

7 years ago

As­traZeneca's prized Imfinzi/treme­li­mum­ab com­bo fails again — this time in head and neck can­cer

7 years ago

Su­per­nus touts AD­HD Phase III da­ta, but re­sults ap­pear to fall short of ex­pec­ta­tions

7 years ago

While we wait for NASH da­ta, Gen­fit re­ports pos­i­tive elafi­bra­nor da­ta in PBC pa­tients

7 years ago

Ab­b­Vie’s trou­bled $10B Ro­va-T can­cer drug pro­gram takes a sud­den turn to­ward the cliff

7 years ago

No­var­tis’ part­ners at Cona­tus have an­oth­er NASH set­back to con­fess to­day

7 years ago

Trou­bled MiMedx ax­es a quar­ter of its work­force in the wake of a C-suite purge

7 years ago

In the wake of deep R&D cuts, Bay­er flags safe­ty con­cerns for a top PhI­II drug

7 years ago

Bis­pecifics vs CAR-T: An­a­lysts se­lect the big win­ners — and losers — at #ASH18's biggest ever dat­a­palooza

7 years ago

Van­da's PhII da­ta of­fer hope for gas­tro­pare­sis pa­tients who have seen no new treat­ments in decades

7 years ago

No­var­tis plots to re­tain hives pa­tients with mon­o­clon­al an­ti­body that out­shines Xo­lair

7 years ago

#ASH18: Can Am­gen break through the BC­MA CAR-T line and take a BiTE of the mul­ti­ple myelo­ma mar­ket? It won't be quick or easy

7 years ago

#ASH18: Al­lo­gene ticks off a high CR rate for up­dat­ed off-the-shelf CAR-T pi­o­neer. But get­ting just the right kind of im­muno­sup­pres­sion is cru­cial

7 years ago

#ASH18: Leg­end Biotech — al­lied with J&J now — con­tin­ues to wow the crowd with their BC­MA CAR-T up­date. What will blue­bird say?

7 years ago

#ASH18: BeiGene works to bust through the check­point crowd with a piv­otal read­out that proves its PD-1 is bet­ter than the rest

7 years ago

Armed with up­dat­ed 24-week PhI­II da­ta, GBT con­vinces FDA to re­view sick­le cell drug un­der ac­cel­er­at­ed path­way

7 years ago

Red­Hill's an­tibi­ot­ic Tal­i­cia edges clos­er to ap­proval, af­ter sec­ond suc­cess­ful Phase III study

7 years ago

All in: No­var­tis adds an­oth­er drug to its fast-grow­ing ra­dio­phar­ma­ceu­ti­cals di­vi­sion

7 years ago
Pharma

J&J pays $500M in cash to grab rights to a new star can­cer drug at ar­genx

7 years ago
Pharma

#ASH18: Blue­bird and Cel­gene didn’t 'break' their next-gen BC­MA CAR-T, so now they’ll dou­ble down on the dose and root for re­al dura­bil­i­ty

7 years ago
First page Previous page 256257258259260261262 Next page Last page
A service from the Financial Times